FDA Requiring Stronger Safety Labels for Opioid Medications
By Stephanie Brown HealthDay Reporter
MONDAY, Aug. 4, 2025 -- The U.S. Food and Drug Administration announced it will now be requiring updated safety labels for all opioid pain medications to better highlight the risks of long-term use, including misuse, addiction, and overdose.
The updated FDA opioid safety labeling is based on new data from two large postmarketing observational studies, which showed serious risks from long-term use. Citing these findings, public input, and the lack of strong evidence supporting long-term effectiveness, the FDA is updating opioid safety labels to support treatment decisions based on the latest evidence.
"The death of almost 1 million Americans during the opioid epidemic has been one of the cardinal failures of the public health establishment," FDA Commissioner Marty Makary, M.D., M.P.H., said in a statement. "This long-overdue labeling change is only part of what needs to be done -- we also need to modernize our approval processes and postmarket monitoring so that nothing like this ever happens again."
The labeling changes will include clearer risk information; stronger dosing warnings; clarified use limits, including removing language that could be misinterpreted as supporting indefinite use; and treatment guidance, emphasizing that long-acting opioids should only be used when other treatments, including short-acting opioids, are ineffective.
The labels will also address safe discontinuation; overdose reversal agents; drug interactions, including combining opioids with gabapentinoids; additional risks with overdose, highlighting new information on postoverdose toxic leukoencephalopathy; and digestive health, including updates about possible esophageal complications.
The FDA is also requiring a new randomized, controlled clinical trial to directly assess the benefits and risks of long-term opioid use. The agency says it will closely monitor the trial's progress.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2025
Read this next
FDA Urges Restrictions, Education on Illegal 7-OH Opioid Products
TUESDAY, July 29, 2025 -- The U.S. Food and Drug Administration is recommending that certain products containing 7-hydroxymitragynine (7-OH) -- an illegal opioid easily accessible...
Doctor's Advice Can Reduce Opioids Taken After Surgery
MONDAY, July 28, 2025 — Some wise counsel in advance can reduce the amount of opioid painkillers a patient takes after orthopedic surgery, new clinic trial results...
FDA Sends Warning Letters to Companies Selling Illegal Opioid Compound
TUESDAY, July 15, 2025 -- The U.S Food and Drug Administration has issued seven warning letters to companies illegally marketing products containing 7-hydroxymitragynine (7-OH)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.